[1]赵德善,乔振华.18F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值[J].国际放射医学核医学杂志,2007,31(3):141-144.
　ZHAO De-shan,QIAO Zhen-hua.The clinical value of 18F-fluorodeoxyglucose PET-CT in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):141-144.
点击复制

18F-氟脱氧葡萄糖PET-CT在淋巴瘤中的应用价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第3期
页码:
141-144
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The clinical value of 18F-fluorodeoxyglucose PET-CT in lymphoma
作者:
赵德善1;  乔振华2
1. 030001 太原, 山西医科大学第一医院核医学科;
2. 030001 太原, 山西医科大学第二医院血液内科
Author(s):
ZHAO De-shan1;  QIAO Zhen-hua2
1. Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Taiyuan 030001, China;
2. Department of Hemotology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China
关键词:
淋巴瘤; 体层摄影术; 发射型计算机; 体层摄影术; X线计算机; 氟脱氧葡萄糖F18
Keywords:
Lymphoma; Tomography; emission-computed; Tomography; X-ray computed; Fluoro-deoxyglucose F18
分类号:
R817.4
摘要:
PET-CT是一种双模式显像方法,可同时获得功能代谢和形态解剖学影像,通过其融合图像显示CT对PET图像的精确定位.18F-氟脱氧葡萄糖(18F-FDG)是一种葡萄糖类似物,可被淋巴瘤细胞摄取.而18F-FDG PET-CT在淋巴瘤的诊断、初始分期、治疗后再分期、治疗反应的评价以及制定放疗计划等方面均有较大的优势,也可在很大程度上避免18F-FDG PET假阳性结果的出现.但PET-CT仅是一种有效的无创伤检查方法,无法替代淋巴瘤的活组织检查。
Abstract:
PET-CT is a dual-modality imaging tool and has a major role in malignant tumors. The CT antoraic data and metabolic 18F-fluorodeoxyglucose (18F-FDG) PET data can be obtained with PET-CT scanner in a single study. The fusion imaging of antomic data and metabolic data provides valuable information to help the precise location of disease and to some extent avoid potential pitfalls. 18F-FDG is a glucose analogue and may markedly accumulate in lymphoma cells. 18F-FDGPET-CT plays a very important role in the detection and staging of lymphoma, restaging after treatment, monitoring treatment response and radiotherapy planning, but isn’t a substitute of biopsy.

参考文献/References:

1 Schillaci D,Danieli R,Manni C,et al.Is SPECT/CT with a hybrid camera useful to improve scintigraphic imaging interpretation?.Nucl Med Commun,2004,25(7):705-710
2 Foo SS,Mitchell PL,Berlangieri SU,et al.Positron emission tomography scanning in the assessment of patients with lymphoma.Intern Med J,2004,34(7):388-397.
3 Rini JN,Leonidas JC,Tomas MB,et al.18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma.J Nucl Med,2003,44(7):1072-1074.
4 Blum RH,Seymour JF,Wirth A,et al.Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin’s lymphoma.Clin Lymphoma,2003,4(1):43-49.
5 Mikosch P,Gallowitsch HJ,Zinke-Cerwenka W,et al.Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.Acta Med Austriaca,2003,30(2):41-47.
6 Raanani P,Shasha Y,Perry C,et al.Is CT scan still necessaiy for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?.Ann Oncol,2006,17(1):117-122.
7 Allen-Auerbach M,Quon A,Weber WA,et al.Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.Mol Imaging Biol,2004,6(6):411-416.
8 Freudenberg LS,Antoch G,Schutt P,et al.FDG-PET/CT in restaging of patients with lymphoma.Eur J Nucl Med Mol Imaging,2004,31(3):325-329.
9 Schaefer NG,Hany TF,Tavema C,et al.Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and Restaging-do we need contrast-enhanced CT?.Radiology,2004,232(3):823-829.
10 Shen YY,Kao A,Yen RF.Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.Oncol Rep,2002,9(2):321-325.
11 Zinzani PL,Fanti S,Battista G,et al.Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients.Br J Cancer,2004,91(5):850-854.
12 Joyce JM,Degirmenci B,Jacobs S,et al.FDG PET/CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.Clin Nucl Med,2005,30(8):564-568.
13 Foss Abrahamsen A,Andersen A,Nome O et al.Long-term risk of second malignancy after treatment of Hodgkin’s disease:the influence of treatment,age and follow-up time.Ann Oncol,2002,13(11):1786-1791.
14 Hoskin P.The price of anticancer intervention.Secondary malignancies after radiotherapy.L&ncet Oncol,2002,(39):577-578.
15 Yahalom J.Transformation in the use of radiation therapy of Hodgkin lymphoma:new concepts and indications lead to modem field design and are assisted by PET imaging and intensity modulated radiationtherapy (IMRT).Eur J Haematol Suppl,2005,75(66):90-97.
16 Brianzoni E,Rossi G,Ancidei S,et al.Radiotherapy planning:PET/CT scanner performances in the definition of gross tumour volume and clinical target volume.Eur J Nucl Med Mol Imaging,2005,32(12):1392-1399.
17 Lee YK,Cook G,Flower MA,et al.Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma.Radiother Oncol,2004,73(3):277-283.
18 Subhas N,Patel PV,Pannu HK,et al.Imaging of pelvic malignancies with in-line FDG PET-CT:case examples and common pitfalls of FDGPET.Radiographics,2005,25(4):1031-1043.
19 Castellucci P,Nanni C,Farsad M,et al.Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:prevalence and scan interpretation.Nucl Med Gommun,2005,26(8):689-694.
20 Castellucci P,Zinzani P,Pourdehnad M,et al.(18) F-FDG PET in malignant lymphoma:significance of positive findings.Eur J Nucl Med Mol Imaging,2005,32(7):749-756.

相似文献/References:

[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
　Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
　Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
　Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[4]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
　Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[5]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[6]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
　Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[7]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[8]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[9]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
　Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
[10]刘淑蓉,孙凯.低辐射剂量冠状动脉成像的研究进展[J].国际放射医学核医学杂志,2016,40(4):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
　Liu Shurong,Sun Kai.The advances of low radiation dose coronary computed tomography angiography imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):293.[doi:10.3760/cma.j.issn.1673-4114.2016.04.011]
[11]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
　Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[12]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[13]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
　Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[14]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
　Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[15]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
　YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[16]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[17]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
　SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[18]张悦,高硕.18F-氟脱氧葡萄糖PET在淋巴瘤中的应用价值[J].国际放射医学核医学杂志,2007,31(5):292.
　ZHANG Yue,GAO Shuo.The value of 18F-fluorodeoxyglucose PET in lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(3):292.
[19]秦文琼,高硕.PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志,2017,41(6):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
　Qin Wenqiong,Gao Shuo.Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):437.[doi:10.3760/cma.j.issn.1673-4114.2017.06.010]
[20]段钰,邓小虎,徐迟峰,等.面部原发性外周T细胞淋巴瘤-非特指型18F-FDG PET/CT显像一例[J].国际放射医学核医学杂志,2017,41(6):455.[doi:10.3760/cma.j.issn.1673-4114.2017.06.014]

备注/Memo

备注/Memo:
收稿日期:2006-09-18。
通讯作者:赵德善,E-mail:deshanzh@hotmail.com
更新日期/Last Update: 1900-01-01